Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-beta (Abeta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Abeta indicate dysregulation of production or clearance of Abeta. Whether dysregulation of Abeta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, >99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Abeta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In non-pathological conditions the clearance of cerebral Aβ exceeds its production [9].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [9]
In the citing paper
“we adapted an in vivo stable isotopic labeling kinetics technique previously described in humans (43).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [43]
In the citing paper
“which is approximately 4-times slower than the turnover rate for the total CNS Aβ peptide (Fig. 6) [31]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [31]
In the citing paper
“The interstitial concentration of Aβ is higher in awake than in sleeping rodents and humans”
From Sleep Drives Metabolite Clearance from the Adult Brain (2013) · cites this paper as [15]
In the citing paper
“In prior SILK studies (19), plasma 13C6-leucine enrichment was found to adequately represent 13C6 labeling in the precursor pool for Aβ synthesis.”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Several earlier studies have shown that some plasma Aβ can enter the CN”
BackgroundSelf-citationOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“In Down syndrome, three copies of APP result in increased production of Aβ, and 100% of individuals with Down syndrome develop Alzheimer disease pathology by age 35 (ref”
Garlick, P. J., McNurlan, M. A., & Preedy, V. R. (1980) · Biochemical Journal · doi:10.1042/bj1920719 · Cited by 973
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Cerebrospinal Fluid in Diseases of the Nervous System.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-517_1 · Cited by 657
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Cited by
Items 101–200 of 627
Storck, S. E., Hartz, A. M. S., Bernard, J., Wolf, A., Kachlmeier, A., Mahringer, A., Weggen, S., Pahnke, J., & Pietrzik, C. U. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.07.017 · Cited by 143
Clusterin as a therapeutic target
Wilson, M. R., & Zoubeidi, A. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1267142 · Cited by 144
Nimmrich, V., & Ebert, U. (2009) · Reviews in the Neurosciences · doi:10.1515/revneuro.2009.20.1.1 · Cited by 139
Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9
Hernandez-Guillamon, M., Mawhirt, S., Blais, S., Montaner, J., Neubert, T. A., Rostagno, A., & Ghiso, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610931 · Cited by 137
Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Niaz, K., Jeandet, P., Clément, C., Mathew, B., Rauf, A., Rengasamy, K. R. R., Sobarzo-Sánchez, E., Ashraf, G. M., et al. (2020) · Molecules · doi:10.3390/molecules25061267 · Cited by 133
Calabrese, B., Shaked, G. M., Tabarean, I. V., Braga, J., Koo, E. H., & Halpain, S. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.02.006 · Cited by 114
Calderón‐Garcidueñas, A. L., & Duyckaerts, C. J. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00023-7 · Cited by 158
Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity
Czirr, E., Castello, N. A., Mosher, K. I., Castellano, J. M., Hinkson, I. V., Lucin, K. M., Baeza-Raja, B., Ryu, J. K., Li, L., Farina, S. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162011 · Cited by 126
“However, evidence indicates that impaired clearance is mainly responsible (Bateman et al., 2006; Roberts et al., 2014).”
BackgroundNuclear receptors as therapeutic targets for Alzheimer's disease
Mandrekar-Colucci, S., & Landreth, G. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.594043 · Cited by 126
Kim, D., Kwon, H. J., & Hyeon, T. (2019) · Advanced Materials · doi:10.1002/adma.201807965 · Cited by 121
Alzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
Galasko, D. R., Graff-Radford, N., May, S., Hendrix, S., Cottrell, B. A., Sagi, S. A., Mather, G., Laughlin, M., Zavitz, K. H., Swabb, E., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815d1048 · Cited by 123
Astrocytes from old Alzheimer's disease mice are impaired in Aβ uptake and in neuroprotection
Iram, T., Trudler, D., Kain, D., Kanner, S., Galron, R., Vassar, R., Barzilai, A., Blinder, P., Fishelson, Z., & Frenkel, D. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.001 · Cited by 115
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 121
Uddin, M. S., & Kabir, M. T. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00197 · Cited by 119
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box
Young, A. L., Oxtoby, N. P., Garbarino, S., Fox, N. C., Barkhof, F., Schott, J. M., & Alexander, D. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00779-6 · Cited by 145
Amyloid β and APP as biomarkers for Alzheimer’s disease
Zetterberg, H., Blennow, K., & Hanse, E. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.08.002 · Cited by 136
Deuterium‐ und tritiummarkierte Verbindungen: Anwendungen in den modernen Biowissenschaften
Atzrodt, J., Derdau, V., Kerr, W. J., & Reid, M. (2017) · Angewandte Chemie · doi:10.1002/ange.201704146 · Cited by 118
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
“Ab is rapidly metabolized in the brain (t½ 2 h) and periphery (t½ in plasma < 10 min) (Bateman et al. 2006).”
BackgroundMollenhauer, B., El-Agnaf, O. M., Marcus, K., Trenkwalder, C., & Schlossmacher, M. G. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.90 · Cited by 113
Aβ-globulomers are formed independently of the fibril pathway
Gellermann, G. P., Byrnes, H., Striebinger, A., Ullrich, K., Mueller, R., Hillen, H., & Barghorn, S. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.01.010 · Cited by 112
Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
Li, Y., Rusinek, H., Butler, T., Glodzik, L., Pirraglia, E., Babich, J. W., Mozley, P. D., Nehmeh, S. A., Pahlajani, S. S., Wang, X. H., et al. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00318-y · Cited by 121
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
“Recently, a study measuring both Aβ production and clearance rates in AD and healthy controls has revealed that the production of Aβ is similar in AD and controls, whereas the clearance rate of Aβ is decreased by around 30% in AD compared with healthy patients, showing that Aβ clearance mechanisms are defective in AD…”
ResultPrecision pharmacology for Alzheimer’s disease
Hampel, H., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J., Dubois, B., Federoff, H. J., Fiandaca, M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 108
Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies
Hillen, H., Barghorn, S., Striebinger, A., Labkovsky, B., Müller, R., Nimmrich, V., Nolte, M. W., Perez-Cruz, C., van der Auwera, I., van Leuven, F., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5721-09.2010 · Cited by 113
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 116
Sundelöf, J., Giedraitis, V., Irizarry, M. C., Sundström, J., Ingelsson, E., Rönnemaa, E., Ärnlöv, J., Gunnarsson, M. D., Hyman, B. T., Basun, H., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.57 · Cited by 113
SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy
Winer, L., Srinivasan, D., Chun, S., Lacomis, D., Jaffa, M., Fagan, A., Holtzman, D. M., Wancewicz, E., Bennett, C. F., Bowser, R., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.593 · Cited by 110
Self-citationAlzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 108
Sankaranarayanan, S., Holahan, M. A., Colussi, D. J., Crouthamel, M., Devanarayan, V., Ellis, J. D., Espeseth, A. S., Gates, A. T., Graham, S. L., Gregro, A. R., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143628 · Cited by 116
The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
Hillen, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01154 · Cited by 106
Cao, J., Herman, A. B., West, G. B., Poe, G., & Savage, V. M. (2020) · Science Advances · doi:10.1126/sciadv.aba0398 · Cited by 105
Distinct Pools of β-Amyloid in Alzheimer Disease–Affected Brain: A Clinicopathologic Study
Steinerman, J. R., Irizarry, M., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B., & Stern, Y. (2008) · Archives of Neurology · doi:10.1001/archneur.65.7.906 · Cited by 104
“5) [8-20] No.”
Sacubitril/valsartan: beyond natriuretic peptides
Singh, J. S. S., Burrell, L. M., Cherif, M., Squire, I. B., Clark, A. L., & Lang, C. C. (2017) · Heart · doi:10.1136/heartjnl-2017-311295 · Cited by 99
Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques
Kumar‐Singh, S. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00380.x · Cited by 94
P‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2020) · The FEBS Journal · doi:10.1111/febs.15148 · Cited by 96
Amyloid imaging in Alzheimer??s disease
Nordberg, A. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3281a47744 · Cited by 97
Copper imbalance in Alzheimer’s disease: Convergence of the chemistry and the clinic
Kepp, K. P., & Squitti, R. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.06.018 · Cited by 96
A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease
Portelius, E., Dean, R. A., Gustavsson, M. K., Andreasson, U., Zetterberg, H., Siemers, E., & Blennow, K. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt30 · Cited by 91
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
“In a more recent study using stable isotope labeling combined with CSF sampling to measure the synthesis rate of Aβ in healthy men, a single oral dose of either 100,140 or 280 mg of this compound lowered CSF Aβ production by 47%, 52%, and 84%, respectively (Bateman et al., 2006, 2009).”
Abramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140327 · Cited by 89
Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study
Silverberg, G. D., Mayo, M., Saul, T., Fellmann, J., Carvalho, J., & McGuire, D. (2008) · Neurology · doi:10.1212/01.wnl.0000316197.04157.6f · Cited by 87
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 84
Self-citationRestored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation
Crouch, P. J., Tew, D. J., Du, T., Nguyen, D. N., Caragounis, A., Filiz, G., Blake, R. E., Trounce, I. A., Soon, C. P. W., Laughton, K., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05870.x · Cited by 88
Yang, H., Inglis, B., Talavage, T. M., Nair, V. V., Yao, J. (., Fitzgerald, B., Schwichtenberg, A. J., & Tong, Y. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221074639 · Cited by 91
Alzheimer’s and ABC transporters — new opportunities for diagnostics and treatment
Pahnke, J., Langer, O., & Krohn, M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.001 · Cited by 81
Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
Marr, R. A., & Hafez, D. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00187 · Cited by 83
Ten Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160550 · Cited by 81
Eisele, Y. S., & Duyckaerts, C. J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1516-y · Cited by 85
Kim, H. J., Ajit, D., Peterson, T. S., Wang, Y., Camden, J. M., Gibson Wood, W., Sun, G. Y., Erb, L., Petris, M., & Weisman, G. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07700.x · Cited by 77
Measuring In Vivo Protein Half-Life
Bojkowska, K., de Sio, F. R. S., Barde, I., Offner, S., Verp, S., Heinis, C., Johnsson, K., & Trono, D. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.03.014 · Cited by 89
Picomolar Amyloid-β Peptides Enhance Spontaneous Astrocyte Calcium Transients
Lee, L., Kosuri, P., & Arancio, O. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130740 · Cited by 74
Renard, D., Castelnovo, G., Wacongne, A., Floch, A., Thouvenot, É., Mas, J., Gabelle, A., Labauge, P. M., & Lehmann, S. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6520-8 · Cited by 86
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition
Cabrera, E., Mathews, P., Mezhericher, E., Beach, T. G., Deng, J., Neubert, T. A., Rostagno, A., & Ghiso, J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.005 · Cited by 78
Kumar, S., Singh, S., Hinze, D., Josten, M., Sahl, H.-G., Siepmann, M., & Walter, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.279133 · Cited by 76
Bateman, R. J., Munsell, L. Y., Chen, X., Holtzman, D. M., & Yarasheski, K. E. (2007) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2007.02.009 · Cited by 76
Self-citationde la Escosura‐Muñiz, A., Plichta, Z., Horák, D., & Merkoçi, A. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.07.086 · Cited by 78
Sleep and Early Cortical Development
Kurth, S., Olini, N., Huber, R., & LeBourgeois, M. (2015) · Current Sleep Medicine Reports · doi:10.1007/s40675-014-0002-8 · Cited by 69
Storck, S. E., & Pietrzik, C. U. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2267-3 · Cited by 79
Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Morgado, I., & Garvey, M. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 71
Ghosal, K., Haag, M., Verghese, P. B., West, T., Veenstra, T., Braunstein, J. B., Bateman, R. J., Holtzman, D. M., & Landreth, G. E. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.001 · Cited by 73
Self-citationP2Y4 Receptor-Mediated Pinocytosis Contributes to Amyloid Beta-Induced Self-Uptake by Microglia
Li, H.-Q., Chen, C., Dou, Y., Wu, H.-J., Liu, Y.-J., Lou, H.-F., Zhang, J.-M., Li, X.-M., Wang, H., & Duan, S. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00544-13 · Cited by 73
Lucey, B. P., Mawuenyega, K. G., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Morris, J. C., & Bateman, R. J. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4202 · Cited by 70
Self-citationCORP: The use of deuterated water for the measurement of protein synthesis
Miller, B. F., Reid, J. J., Price, J. C., Lin, H. L., Atherton, P. J., & Smith, K. (2020) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00855.2019 · Cited by 83
Nascimento, K. K. F. D., Silva, K. P., Malloy-Diniz, L. F., Butters, M. A., & Diniz, B. S. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.024 · Cited by 69
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 76
Cook, J. J., Wildsmith, K. R., Gilberto, D. B., Holahan, M. A., Kinney, G. G., Mathers, P. D., Michener, M. S., Price, E. A., Shearman, M. S., Simon, A. J., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1381-10.2010 · Cited by 72
Self-citationTalwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S. S., Agarwal, R., Taneja, V., & Kukreti, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9390-0 · Cited by 80
Photothermal ablation of amyloid aggregates by gold nanoparticles
Triulzi, R. C., Dai, Q. L., Zou, J., Leblanc, R. M., Gu, Q., Orbulescu, J., & Huo, Q. (2007) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2007.12.006 · Cited by 70
Corona, A. W., Kodoma, N., Casali, B. T., & Landreth, G. E. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9627-8 · Cited by 65
CSF Biomarkers: Pinpointing Alzheimer Pathogenesis
Mattsson, N., Blennow, K., & Zetterberg, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04944.x · Cited by 66
Liebsch, F., Kulic, L., Teunissen, C., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa-Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 68
Self-citationAntioxidant Thymoquinone and Its Potential in the Treatment of Neurological Diseases
Исаев, Н. К., Генрихс, Е. Е., & Stelmashook, E. V. (2023) · Antioxidants · doi:10.3390/antiox12020433 · Cited by 77
Ashford, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150381 · Cited by 68
Dal‐Pan, A., Dudonné, S., Bourassa, P., Bourdoulous, M., Tremblay, C., Desjardins, Y., & Calon, F. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160281 · Cited by 70
(2013) · PubMed · Cited by 66
Role of Neuron and Glia in Alzheimer’s Disease and Associated Vascular Dysfunction
Bandyopadhyay, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.653334 · Cited by 61
Autophagy is involved in oligodendroglial precursor-mediated clearance of amyloid peptide
Li, W., Tang, Y., Fan, Z., Meng, Y., Yang, G., Luo, J., & Ke, Z.-J. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-27 · Cited by 65
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. H. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 66
Gut microbiota in neurological diseases: Melatonin plays an important regulatory role
Ahmadi, S., Taghizadieh, M., Mehdizadehfar, E., Hasani, A., Fard, J. K., Feizi, H., Hamishehkar, H., Ansarin, M., Yekani, M., & Memar, M. Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116487 · Cited by 67
Carlock, C., Wu, J., Shim, J., Moreno-Gonzalez, I., Pitcher, M. R., Hicks, J., Suzuki, A., Iwata, J., Quevado, J., & Lou, Y. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.142 · Cited by 59
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 68
The Concentration of Soluble Extracellular Amyloid-β Protein in Acute Brain Slices from CRND8 Mice
Waters, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015709 · Cited by 62
Sink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels
Zhang, Y., & Lee, D. H. S. (2011) · The Neuroscientist · doi:10.1177/1073858410381532 · Cited by 57
In vivo kinetic approach reveals slow SOD1 turnover in the CNS
Crisp, M. J., Mawuenyega, K. G., Patterson, B. W., Reddy, N. C., Chott, R., Self, W. K., Weihl, C. C., Jockel-Balsarotti, J., Varadhachary, A. S., Bucelli, R. C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80705 · Cited by 59
Self-citationOn the subject of rigor in the study of amyloid β-protein assembly
Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt203 · Cited by 61
Merchant, K., Cedarbaum, J. M., Brundin, P., Dave, K. D., Eberling, J. L., Espay, A. J., Hutten, S. J., Javidnia, M., Luthman, J., Maetzler, W., et al. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181471 · Cited by 63
SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases
Paterson, R. W., Gabelle, A., Lucey, B. P., Barthélemy, N. R., Leckey, C. A., Hirtz, C., Lehmann, S., Sato, C., Patterson, B. W., West, T., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0222-0 · Cited by 61
Self-citationStorelli, F., Billington, S., Kumar, A. R., & Unadkat, J. D. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2035 · Cited by 57
Targeting Sleep Physiology to Modulate Glymphatic Brain Clearance
van Hattem, T., Verkaar, L., Krugliakova, E., Adelhöfer, N., Zeising, M., Drinkenburg, W. H. I. M., Claassen, J. A. H. R., Bódizs, R., Dresler, M., & Rosenblum, Y. (2024) · Physiology · doi:10.1152/physiol.00019.2024 · Cited by 75
Pharmacotherapeutic targets in Alzheimer's disease
Biran, Y., Masters, C. L., Barnham, K. J., Bush, A. I., & Adlard, P. A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00595.x · Cited by 57
Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics
Mawuenyega, K. G., Kasten, T., Sigurdson, W., & Bateman, R. J. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.04.031 · Cited by 58
Self-citationSmall molecule inhibitors of Abetaassembly
LeVine, H. (2007) · Amyloid · doi:10.1080/13506120701461020 · Cited by 68
Ding, J., Zhao, C., Hao, X., & Jiao, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70709 · Cited by 59
Supraphysiologic-dose anabolic–androgenic steroid use: A risk factor for dementia?
Kaufman, M. J., Kanayama, G., Hudson, J. I., & Pope, H. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.014 · Cited by 64
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 59
In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS
Wildsmith, K. R., Basak, J. M., Patterson, B. W., Pyatkivskyy, Y., Kim, J., Yarasheski, K. E., Wang, J. X., Mawuenyega, K. G., Jiang, H., Parsadanian, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038013 · Cited by 58
“ApoE genotype was determined by PCR in the Washington University ADRC Genetics Core [52].”
BackgroundMethodResultInfluentialSelf-citationBaker-Nigh, A. T., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Kasten, T., Franklin, E. E., Liao, F., Jiang, H., Holtzman, D., Cairns, N. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721779 · Cited by 54
“5–1) and age-matched controls were recruited in A metabolism studies (53).”
MethodSelf-citationSelkoe, D. J. (2006) · Nature Medicine · doi:10.1038/nm0706-758 · Cited by 58
Metadata
- Authors
- Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Venue
- Nature Medicine
- Published
- 2006-06-25
- Volume
- 12
- Issue
- 7
- Pages
- 856-861
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2983090
- OpenAlex
- W2171259749
- Cited by
- 599
- References
- 41
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 33 · 2023: 27 · 2022: 19 · 2021: 28 · 2020: 38 · 2019: 34 · 2018: 23 · 2017: 35 · 2016: 36 · 2015: 40 · 2014: 31 · 2013: 30 · 2012: 40
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eli Lilly and Company
- American Academy of Neurology
- National Institutes of Health (5p41rr000954-34)
- National Institute on Aging (L30 AG024455, K08AG027091, P 50 AG05681, P50AG005681)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 056341, P30DK056341)
- National Center for Research Resources (P41-RR000954, RR-000954, M01-RR00036, M01RR000036)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, Alzheimer's disease, cerebrospinal fluid, amyloid precursor protein, biomarkers
- MeSH terms
- Amino Acid Sequence, Humans, Models, Molecular, Molecular Sequence Data, Protein Conformation, Biomarkers, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.